Pasar al contenido principal

NUEVA FORMULACION DE VACUNAS RECOMBINANTES ANTITUMORALES BASADA EN GRANULOS DE SECRECION CON LIBERACION SOSTENIDA

PID2022-136845OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The biological activity of therapeutic proteins, upon intracellular delivery, is dramatically minimized by lysosomal proteolytic digestion. This is a limitation when developing cell-targeted pharmaceuticals that penetrate target cells via receptor recognition and endosomal engulfment. Since proteins benefit from functional and conformational versatility, editable by genetic engineering, endosomolytic protein domains are often fused to the functional polypeptide to promote their cytosolic delivery, aiming at minimizing proteolysis in mature lysosomes. This straightforward strategy has, however, rendered irregular results, linked to the fusogenic nature of most of the tested domains. Alternatively, proteolysis of protein drugs might be controlled by bypassing the lysosomal route, forcing an unconventional traffic of the uptaken protein material to be secreted from the endoplasmic reticulum (ER). This possibility, used in nature by several plant and microbial proteins, has been evaluated here by functionalizing a protein-only antitumoral drug, based on a cell-targeted diphtheria toxin, with a C-terminal KDEL motif. Thus, if KDEL were able to reprogram the intracellular trafficking, KDEL-tagged cell delivered proteins would be expected to avoid the lysosomal degradation, resulting in enhanced stability and activity. The obtained results validate this hypothesis and point out KDEL as a promising functional agent in cell-targeted protein drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Chellou-Bakkali, Sara|||0009-0007-1643-4558
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Márquez-Martínez, Merce|||0000-0003-2157-5850
  • Costa, Manuela|||0000-0001-6251-7900
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Structural dynamism confers intriguing applications to biocompatible materials. Here, we present a protein-based, self-organizing microscale material designed to mimic pathogen-like features. In this formulation, the building block proteins shift their organization through monomeric, microscale, or oligomeric nanoscale states, which is expected to enhance antigen uptake and immune activation. To validate the system, several CT26-derived tumor neoantigens, namely, Ubqln1, AHSL and Phf3, have been assembled as mixed granules, leaking nanoscale protein oligomers. When challenging dendritic cells, this formulation enhanced the expression of the activation markers CD40 and MHC II compared with soluble antigens, underscoring the material's ability to potentiate antigen-presenting functions. While many antigens are attractive targets due to their unique expression in malignant cells, their poor immunogenicity in soluble versions may render them ineffective. The present approach represents a transversal and feasible tool to enhance the immunogenicity of protein antigens through a dynamic material platform that expands their translational potential.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

GFP-like protein scaffolds for antigen grafting, Soluble and stable neoantigen display in mammalian-compatible platforms

  • Parladé, Eloi|||0000-0001-5750-550X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Chellou-Bakkali, Sara|||0009-0007-1643-4558
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Subunit vaccines are often limited by poor solubility and structural instability, affecting their ability to induce strong immune responses. Scaffold-based antigen display offers a promising solution, but translating designs into stable, scalable proteins remains challenging. Here, we present a pipeline for selecting and inserting tumor-derived peptide sequences into β-barrel protein frameworks, using both GFP and the structurally similar G2 domain of the mouse nidogen. We validate the ASP173 loop in GFP as an effective insertion site, accommodating a double-peptide construct, as well as two distinct single peptides, without compromising folding or fluorescence. We further show that this design logic extends to the mouse nidogen G2 domain, which we employ as a host-native scaffold to carry the inserted epitope. The resulting constructs retain structural integrity and thermal stability, supporting their use in preclinical models and facilitating future applications in human health. This work establishes a modular, mammalian-compatible platform for stable tumor-associated peptide presentation, thereby advancing the development of next-generation cancer vaccines.
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs

  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Alba Castellon, Lorena
  • Arena Ailen, Lourdes
  • Sánchez Quiroga, Julieta María
  • Casanova Rigat, Isolda
  • Mangues Bafalluy, Ramon
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
  • Unzueta Elorza, Ugutz
The biological activity of therapeutic proteins, upon intracellular delivery, is dramatically minimized by lysosomal proteolytic digestion. This is a limitation when developing cell-targeted pharmaceuticals that penetrate target cells via receptor recognition and endosomal engulfment. Since proteins benefit from functional and conformational versatility, editable by genetic engineering, endosomolytic protein domains are often fused to the functional polypeptide to promote their cytosolic delivery, aiming at minimizing proteolysis in mature lysosomes. This straightforward strategy has, however, rendered irregular results, linked to the fusogenic nature of most of the tested domains. Alternatively, proteolysis of protein drugs might be controlled by bypassing the lysosomal route, forcing an unconventional traffic of the uptaken protein material to be secreted from the endoplasmic reticulum (ER). This possibility, used in nature by several plant and microbial proteins, has been evaluated here by functionalizing a protein-only antitumoral drug, based on a cell-targeted diphtheria toxin, with a C-terminal KDEL motif. Thus, if KDEL were able to reprogram the intracellular trafficking, KDEL-tagged cell delivered proteins would be expected to avoid the lysosomal degradation, resulting in enhanced stability and activity. The obtained results validate this hypothesis and point out KDEL as a promising functional agent in cell-targeted protein drugs., The authors appreciate the financial support received for the development of multimeric recombinant drugs, from Agencia Estatal de Investigacion ´ (PDC2022-133858-I00 to EV, PID2022-136845OB-I00 to EV and AV, PID2020-116174RB-I00 to AV and CNS2024-154280 to UU), AGAUR (SGR2021-00092 to AV and 2021SGR-01140 to RM) and Instituto de Salud Carlos III (PI24/01476 to RM, and PI20/00400 and PI23/00318 to UU) co-funded by European Regional Development Fund (ERDF, a way to make Europe)., Peer Reviewed, 3 - Salut i Benestar
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Lyophilization of biomimetic amyloids preserves their regulatable, endocrine- like functions for nanoparticle release

  • Teixeira De Pinho Favaro, Marianna
  • Lopez Laguna, Hector
  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Alba Castellon, Lorena
  • Sánchez Quiroga, Julieta María
  • Casanova Rigat, Isolda
  • Unzueta Elorza, Ugutz
  • Mangues, Ramón
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
The secretory granules from the mammalian endocrine system are functional amyloids that act as dynamic depots to store and release protein hormones into the bloodstream. The controlled in vitro coordination between divalent cations and solvent-exposed histidine residues triggers reversible, cross-molecular interactions that result in granular protein aggregates with protein-leaking properties. While these synthetic particles are mechanically stable, they progressively disintegrate and release their protein building blocks, mimicking the performance of secretory granules. Envisaged as delivery systems for endocrine-like, time-sustained protein release, their clinical applicability should be supported by robust storage procedures, so far unset. Being lyophilization a desirable storage method for protein drugs, how this procedure could preserve the performance of clinically oriented functional amyloids is a neglected issue. We have here explored, tailored and validated lyophilization as an industrially and clinically friendly, fully scalable approach to the storage of functional amyloids aimed at secretion of protein-only nanoparticles. By doing so, protein-protein interactions in such materials have been characterized, and citrate identified as an efficient modulator of the temporal secretion profile, through which the sustainability of the leaking process can be finely regulated., We appreciate the support from AEI (Spain) for the development of multimeric recombinant drugs (PID2019–105416RB-I00/AEI/ 10.13039/501100011033 and PDC2022–133858-I00 to E.V., and PID2022–1368450 OB-10/AEI/10.13039/501100011033 to AV and EV) and to Instituto de Salud Carlos III (PI20/00400 and PI23/00318 to U.U., and PI21/00150 to R.M.) co-funded by European Regional Development Fund (ERDF, a way to make Europe). JMS is supported with a María Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (“Financed by European Union-Next GenerationEU”).The authors also appreciate the financial support received from AGAUR (2021SGR00092 to A.V. and 2021SGR01140 to R.M), from CIBER -Consorcio Centro de Investigacion´ Biomédica en Red- (CB06/01/0014 and CB06/01/1031), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion, ´ through intramural projects (NANO4CANCER to A.V.,NANOREMOTE to E.V. and 4NANOMETS to R.M.). U.U. is supported by Miguel Servet contract (CP19/ 00028) from ISCIII co-funded by European Social Fund (ESF investing in your future), L. A-C is supported by AECC (Spain) Postdoctoral fellowship (POSTD20070ALBA). We also acknowledge the support from Microscopy Service, the Proteomics and Structural Biology Service and the Cell Culture, Antibody Production and Cytometry Service, all in the UAB. Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/ IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-productio n-platform-ppp/)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms

  • Parladé Molist, Eloi|||0000-0001-5750-550X
  • Favaro, Marianna TP
  • Chellou Bakkali, Sara
  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Lopez Laguna, Hector
  • Villaverde, Antoni
  • Vázquez Gómez, Esther
Subunit vaccines are often limited by poor solubility and structural instability, affecting their ability to induce strong immune responses. Scaffold-based antigen display offers a promising solution, but translating designs into stable, scalable proteins remains challenging. Here, we present a pipeline for selecting and inserting tumor-derived peptide sequences into ß-barrel protein frameworks, using both GFP and the structurally similar G2 domain of the mouse nidogen. We validate the ASP173 loop in GFP as an effective insertion site, accommodating a double-peptide construct, as well as two distinct single peptides, without compromising folding or fluorescence. We further show that this design logic extends to the mouse nidogen G2 domain, which we employ as a host-native scaffold to carry the inserted epitope. The resulting constructs retain structural integrity and thermal stability, supporting their use in preclinical models and facilitating future applications in human health. This work establishes a modular, mammalian-compatible platform for stable tumor-associated peptide presentation, thereby advancing the development of next-generation cancer vaccines., The study was mainly funded by the Agencia Española de Investigación (AEI) through the project PID2022-136845OB-10/AEI/10.13039/501100011033 to E.V. and by AGAUR through the project SGR 2021 00092 to A.V. We would like to thank the ISCIII for funding CIBER-BBN (CB06/01/0014 and NANOREMOTE) and the Ministry of Science for funding the ICTS Platform Nanbiosis. The production of the fusion proteins was assisted, in part, by the Protein Production (PPP) Unit of the Platform Nanbiosis of the CIBER-BBN/IBB. Molecular graphics were performed with UCSF Chimera and ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from the National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. ESI-TOF and ICP-MS experiments were performed at Servei d'Anàlisi Química (SAQ) in Universitat Autònoma de Barcelona (UAB). Fluorimetry experiments were performed at Servei de Genòmica i Espectroscòpia de Biomolècules (SGiEB) in UAB. Electron microscopy was performed at the Servei de Microscòpia i Difracció de Raigs X (UAB). MALDI-TOF experiments were performed at Unitat d'Espectrometria de Masses de Caracterització Molecular CCiTUB in Universitat de Barcelona (UB)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

A structurally dynamic pathogen-mimicking biomaterial is an efficient activator of dendritic cells

  • Lopez Laguna, Hector
  • Favaro, Marianna TP
  • Chellou Bakkali, Sara
  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Parladé Molist, Eloi|||0000-0001-5750-550X
  • Márquez Martínez, Mercedes
  • Costa, Manuela
  • Roher Armentia, Nerea
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
Structural dynamism confers intriguing applications to biocompatible materials. Here, we present a protein-based, self-organizing microscale material designed to mimic pathogen-like features. In this formulation, the building block proteins shift their organization through monomeric, microscale, or oligomeric nanoscale states, which is expected to enhance antigen uptake and immune activation. To validate the system, several CT26-derived tumor neoantigens, namely, Ubqln1, AHSL and Phf3, have been assembled as mixed granules, leaking nanoscale protein oligomers. When challenging dendritic cells, this formulation enhanced the expression of the activation markers CD40 and MHC II compared with soluble antigens, underscoring the material’s ability to potentiate antigen-presenting functions. While many antigens are attractive targets due to their unique expression in malignant cells, their poor immunogenicity in soluble versions may render them ineffective. The present approach represents a transversal and feasible tool to enhance the immunogenicity of protein antigens through a dynamic material platform that expands their translational potential., The study was mainly funded by the Agencia Española de Investigación (AEI) through the project PID2022− 136845OB-10/AEI/10.13039/501100011033 to E.V. and by AGAUR through the project SGR 2021 00092 to A.V. H.L.L. was supported by a JDC2023−051795-I. We would like to thank the ISCIII for funding CIBER-BBN (CB06/01/0014 and NANOREMOTE) and the Ministry of Science for funding the ICTS Platform Nanbiosis., Peer Reviewed, 3 - Salut i Benestar
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Hybrid micro-/nanoprotein platform provides endocrine-like and extracellular matrix-like cell delivery of growth factors

  • Lopez Laguna, Hector
  • Tsimbouri, Penelope M.
  • Jayawarna, Vineetha
  • Rigou, Ioanna
  • Serna, Naroa
  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz
  • Salmerón Sánchez, Manuel
  • Vázquez Gómez, Esther
  • Dalby, Matthew J.
  • Villaverde Corrales, Antonio
Protein materials are versatile tools in diverse biomedical fields. Among them, artificial secretory granules (SGs), mimicking those from the endocrine system, act as mechanically stable reservoirs for the sustained release of proteins as oligomeric functional nanoparticles. Only validated in oncology, the physicochemical properties of SGs, along with their combined drug-releasing and scaffolding abilities, make them suitable as smart topographies in regenerative medicine for the prolonged delivery of growth factors (GFs). Thus, considering the need for novel, safe, and cost-effective materials to present GFs, in this study, we aimed to biofabricate a protein platform combining both endocrine-like and extracellular matrix fibronectin-derived (ECM-FN) systems. This approach is based on the sustained delivery of a nanostructured histidine-tagged version of human fibroblast growth factor 2. The GF is presented onto polymeric surfaces, interacting with FN to spontaneously generate nanonetworks that absorb and present the GF in the solid state, to modulate mesenchymal stromal cell (MSC) behavior. The results show that SGs-based topographies trigger high rates of MSCs proliferation while preventing differentiation. While this could be useful in cell therapy manufacture demanding large numbers of unspecialized MSCs, it fully validates the hybrid platform as a convenient setup for the design of biologically active hybrid surfaces and in tissue engineering for the controlled manipulation of mammalian cell growth., The study was mainly funded by the Agencia Española de Investigacioń (AEI) through the project PID2020-116174RBI00 granted to A.V. The authors are indebted to AEI for granting additional projects on the construction of protein materials of clinical interest (PID2019-105416RB-I00/AEI/10.13039/ 501100011033 and PDC2022-133858-I00 to E.V., PID2022- 1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.), to AGAUR (SGR 2021 00092 to A.V.), and to ISCIII (PI20/00400 and PI23/00318 to UU) co-funded by European Regional Development Fund (ERDF, a way to make Europe). U.U. was supported by the Miguel Servet contract (CP19/ 00028) from ISCIII, co-funded by the European Social Fund (ESF investing in your future). A.V. received an ICREA ACADEMIA award. M.J.D. is also indebted to the EPSRC grant (EP/P001114/1). We would like to thank ISCIII for funding through CIBER-BBN (CB06/01/0014) and the Ministry of Science for funding the ICTS Platform Nanbiosis. H.L.-L. received a predoctoral fellowship from AGAUR (2019 FI_B 00352)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Biomimetic protein materials for adjuvant-free dermal penetration

  • Favaro, Marianna TP
  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Sánchez Quiroga, Julieta María
  • Escribano Ferrer, Elvira
  • Huaca, Vanessa
  • Miranda Tovar, Eva
  • Unzueta Elorza, Ugutz
  • Parladé Molist, Eloi|||0000-0001-5750-550X
  • Vázquez Gómez, Esther
  • Mangues Bafalluy, Ramon
  • Villaverde Corrales, Antonio
  • Casanova Rigat, Isolda
The effective dermal delivery of functional proteins could substantially improve therapeutic options for common skin disorders, in which current lipid-based or invasive strategies face efficacy and safety limitations. We report a biomimetic protein depot platform based on granular, nontoxic amyloids generated through Zn-mediated coordination of hexahistidine-tagged proteins. Functionalization of these materials with either the cell-penetrating peptide R9 or the tight junction modulator c-CPE, the C-terminal region of the Clostridium perfringens enterotoxin, enabled a systematic evaluation of transdermal penetration in mouse models. Whereas plain and R9-functionalized granules showed restricted permeation, c-CPE-functionalized granules achieved consistent distribution through the dermis into the hypodermal layers. These findings establish self-assembled protein amyloids as a promising and adaptable class of biomaterials for dermal protein delivery. Also, the ability of c-CPE to enhance permeability without auxiliary adjuvants, lipids, or invasive methods highlights the translational potential of this system for clinically applicable, noninvasive management of cutaneous conditions., The study was funded by the Agencia Española de Investigación (AEI) through Project PID2020-116174RB-I00 granted to A.V. The authors are also indebted to AEI for granting additional projects on the construction of protein materials with clinical applications, namely, PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V. and CNS2024-154280 to U.U.; to AGAUR for 2024 LLAV 00077, UAB to E.V., SGR 2021-00092 to A.V., and 2021 SGR-01140 to R.M.; and to ISCIII for PI20/00400 and PI23/00318 to U.U., PI24/00012 to I.C., and PI21/00150 and PI24/01476 to R.M., cofunded by European Regional Development Fund (ERDF) (A Way to Make Europe). J.M.S. was supported with a Mari ́ a Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (Financed by European Union-Next GenerationEU). We thank ISCIII for funding CIBER-BBN (CB06/01/0014 and CB06/01/1031) and the Ministry of Science for funding the ICTS Platform Nanbiosis., Peer Reviewed, 3 - Salut i Benestar
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs

  • Voltà Durán, Eric
  • Alba Castellon, Lorena
  • Arena Ailen, Lourdes
  • Sánchez Quiroga, Julieta María
  • Casanova Rigat, Isolda
  • Mangues Bafalluy, Ramon
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
  • Unzueta Elorza, Ugutz
The biological activity of therapeutic proteins, upon intracellular delivery, is dramatically minimized by lysosomal proteolytic digestion. This is a limitation when developing cell-targeted pharmaceuticals that penetrate target cells via receptor recognition and endosomal engulfment. Since proteins benefit from functional and conformational versatility, editable by genetic engineering, endosomolytic protein domains are often fused to the functional polypeptide to promote their cytosolic delivery, aiming at minimizing proteolysis in mature lysosomes. This straightforward strategy has, however, rendered irregular results, linked to the fusogenic nature of most of the tested domains. Alternatively, proteolysis of protein drugs might be controlled by bypassing the lysosomal route, forcing an unconventional traffic of the uptaken protein material to be secreted from the endoplasmic reticulum (ER). This possibility, used in nature by several plant and microbial proteins, has been evaluated here by functionalizing a protein-only antitumoral drug, based on a cell-targeted diphtheria toxin, with a C-terminal KDEL motif. Thus, if KDEL were able to reprogram the intracellular trafficking, KDEL-tagged cell delivered proteins would be expected to avoid the lysosomal degradation, resulting in enhanced stability and activity. The obtained results validate this hypothesis and point out KDEL as a promising functional agent in cell-targeted protein drugs., The authors appreciate the financial support received for the development of multimeric recombinant drugs, from Agencia Estatal de Investigacion ´ (PDC2022-133858-I00 to EV, PID2022-136845OB-I00 to EV and AV, PID2020-116174RB-I00 to AV and CNS2024-154280 to UU), AGAUR (SGR2021-00092 to AV and 2021SGR-01140 to RM) and Instituto de Salud Carlos III (PI24/01476 to RM, and PI20/00400 and PI23/00318 to UU) co-funded by European Regional Development Fund (ERDF, a way to make Europe)., Peer Reviewed, 3 - Salut i Benestar, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hybrid micro-/nanoprotein platform provides endocrine-like and extracellular matrix-like cell delivery of growth factors

  • Lopez Laguna, Hector
  • Tsimbouri, Penelope M.
  • Jayawarna, Vineetha
  • Rigou, Ioanna
  • Serna, Naroa
  • Voltà Durán, Eric
  • Unzueta Elorza, Ugutz
  • Salmerón Sánchez, Manuel
  • Vázquez Gómez, Esther
  • Dalby, Matthew J.
  • Villaverde Corrales, Antonio
Protein materials are versatile tools in diverse biomedical fields. Among them, artificial secretory granules (SGs), mimicking those from the endocrine system, act as mechanically stable reservoirs for the sustained release of proteins as oligomeric functional nanoparticles. Only validated in oncology, the physicochemical properties of SGs, along with their combined drug-releasing and scaffolding abilities, make them suitable as smart topographies in regenerative medicine for the prolonged delivery of growth factors (GFs). Thus, considering the need for novel, safe, and cost-effective materials to present GFs, in this study, we aimed to biofabricate a protein platform combining both endocrine-like and extracellular matrix fibronectin-derived (ECM-FN) systems. This approach is based on the sustained delivery of a nanostructured histidine-tagged version of human fibroblast growth factor 2. The GF is presented onto polymeric surfaces, interacting with FN to spontaneously generate nanonetworks that absorb and present the GF in the solid state, to modulate mesenchymal stromal cell (MSC) behavior. The results show that SGs-based topographies trigger high rates of MSCs proliferation while preventing differentiation. While this could be useful in cell therapy manufacture demanding large numbers of unspecialized MSCs, it fully validates the hybrid platform as a convenient setup for the design of biologically active hybrid surfaces and in tissue engineering for the controlled manipulation of mammalian cell growth., The study was mainly funded by the Agencia Española de Investigacioń (AEI) through the project PID2020-116174RBI00 granted to A.V. The authors are indebted to AEI for granting additional projects on the construction of protein materials of clinical interest (PID2019-105416RB-I00/AEI/10.13039/ 501100011033 and PDC2022-133858-I00 to E.V., PID2022- 1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.), to AGAUR (SGR 2021 00092 to A.V.), and to ISCIII (PI20/00400 and PI23/00318 to UU) co-funded by European Regional Development Fund (ERDF, a way to make Europe). U.U. was supported by the Miguel Servet contract (CP19/ 00028) from ISCIII, co-funded by the European Social Fund (ESF investing in your future). A.V. received an ICREA ACADEMIA award. M.J.D. is also indebted to the EPSRC grant (EP/P001114/1). We would like to thank ISCIII for funding through CIBER-BBN (CB06/01/0014) and the Ministry of Science for funding the ICTS Platform Nanbiosis. H.L.-L. received a predoctoral fellowship from AGAUR (2019 FI_B 00352)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lyophilization of biomimetic amyloids preserves their regulatable, endocrine- like functions for nanoparticle release

  • Teixeira De Pinho Favaro, Marianna
  • Lopez Laguna, Hector
  • Voltà Durán, Eric
  • Alba Castellon, Lorena
  • Sánchez Quiroga, Julieta María
  • Casanova Rigat, Isolda
  • Unzueta Elorza, Ugutz
  • Mangues, Ramón
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
The secretory granules from the mammalian endocrine system are functional amyloids that act as dynamic depots to store and release protein hormones into the bloodstream. The controlled in vitro coordination between divalent cations and solvent-exposed histidine residues triggers reversible, cross-molecular interactions that result in granular protein aggregates with protein-leaking properties. While these synthetic particles are mechanically stable, they progressively disintegrate and release their protein building blocks, mimicking the performance of secretory granules. Envisaged as delivery systems for endocrine-like, time-sustained protein release, their clinical applicability should be supported by robust storage procedures, so far unset. Being lyophilization a desirable storage method for protein drugs, how this procedure could preserve the performance of clinically oriented functional amyloids is a neglected issue. We have here explored, tailored and validated lyophilization as an industrially and clinically friendly, fully scalable approach to the storage of functional amyloids aimed at secretion of protein-only nanoparticles. By doing so, protein-protein interactions in such materials have been characterized, and citrate identified as an efficient modulator of the temporal secretion profile, through which the sustainability of the leaking process can be finely regulated., We appreciate the support from AEI (Spain) for the development of multimeric recombinant drugs (PID2019–105416RB-I00/AEI/ 10.13039/501100011033 and PDC2022–133858-I00 to E.V., and PID2022–1368450 OB-10/AEI/10.13039/501100011033 to AV and EV) and to Instituto de Salud Carlos III (PI20/00400 and PI23/00318 to U.U., and PI21/00150 to R.M.) co-funded by European Regional Development Fund (ERDF, a way to make Europe). JMS is supported with a María Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (“Financed by European Union-Next GenerationEU”).The authors also appreciate the financial support received from AGAUR (2021SGR00092 to A.V. and 2021SGR01140 to R.M), from CIBER -Consorcio Centro de Investigacion´ Biomédica en Red- (CB06/01/0014 and CB06/01/1031), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion, ´ through intramural projects (NANO4CANCER to A.V.,NANOREMOTE to E.V. and 4NANOMETS to R.M.). U.U. is supported by Miguel Servet contract (CP19/ 00028) from ISCIII co-funded by European Social Fund (ESF investing in your future), L. A-C is supported by AECC (Spain) Postdoctoral fellowship (POSTD20070ALBA). We also acknowledge the support from Microscopy Service, the Proteomics and Structural Biology Service and the Cell Culture, Antibody Production and Cytometry Service, all in the UAB. Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/ IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-productio n-platform-ppp/)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biomimetic protein materials for adjuvant-free dermal penetration

  • Favaro, Marianna TP
  • Voltà Durán, Eric
  • Sánchez Quiroga, Julieta María
  • Escribano Ferrer, Elvira
  • Huaca, Vanessa
  • Miranda Tovar, Eva
  • Unzueta Elorza, Ugutz
  • Parladé Molist, Eloi
  • Vázquez Gómez, Esther
  • Mangues Bafalluy, Ramon
  • Villaverde Corrales, Antonio
  • Casanova Rigat, Isolda
The effective dermal delivery of functional proteins could substantially improve therapeutic options for common skin disorders, in which current lipid-based or invasive strategies face efficacy and safety limitations. We report a biomimetic protein depot platform based on granular, nontoxic amyloids generated through Zn-mediated coordination of hexahistidine-tagged proteins. Functionalization of these materials with either the cell-penetrating peptide R9 or the tight junction modulator c-CPE, the C-terminal region of the Clostridium perfringens enterotoxin, enabled a systematic evaluation of transdermal penetration in mouse models. Whereas plain and R9-functionalized granules showed restricted permeation, c-CPE-functionalized granules achieved consistent distribution through the dermis into the hypodermal layers. These findings establish self-assembled protein amyloids as a promising and adaptable class of biomaterials for dermal protein delivery. Also, the ability of c-CPE to enhance permeability without auxiliary adjuvants, lipids, or invasive methods highlights the translational potential of this system for clinically applicable, noninvasive management of cutaneous conditions., The study was funded by the Agencia Española de Investigación (AEI) through Project PID2020-116174RB-I00 granted to A.V. The authors are also indebted to AEI for granting additional projects on the construction of protein materials with clinical applications, namely, PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V. and CNS2024-154280 to U.U.; to AGAUR for 2024 LLAV 00077, UAB to E.V., SGR 2021-00092 to A.V., and 2021 SGR-01140 to R.M.; and to ISCIII for PI20/00400 and PI23/00318 to U.U., PI24/00012 to I.C., and PI21/00150 and PI24/01476 to R.M., cofunded by European Regional Development Fund (ERDF) (A Way to Make Europe). J.M.S. was supported with a Mari ́ a Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (Financed by European Union-Next GenerationEU). We thank ISCIII for funding CIBER-BBN (CB06/01/0014 and CB06/01/1031) and the Ministry of Science for funding the ICTS Platform Nanbiosis., Peer Reviewed, 3 - Salut i Benestar, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms

  • Parladé Molist, Eloi
  • Favaro, Marianna TP
  • Chellou Bakkali, Sara
  • Voltà Durán, Eric
  • Lopez Laguna, Hector
  • Villaverde, Antoni
  • Vázquez Gómez, Esther
Subunit vaccines are often limited by poor solubility and structural instability, affecting their ability to induce strong immune responses. Scaffold-based antigen display offers a promising solution, but translating designs into stable, scalable proteins remains challenging. Here, we present a pipeline for selecting and inserting tumor-derived peptide sequences into ß-barrel protein frameworks, using both GFP and the structurally similar G2 domain of the mouse nidogen. We validate the ASP173 loop in GFP as an effective insertion site, accommodating a double-peptide construct, as well as two distinct single peptides, without compromising folding or fluorescence. We further show that this design logic extends to the mouse nidogen G2 domain, which we employ as a host-native scaffold to carry the inserted epitope. The resulting constructs retain structural integrity and thermal stability, supporting their use in preclinical models and facilitating future applications in human health. This work establishes a modular, mammalian-compatible platform for stable tumor-associated peptide presentation, thereby advancing the development of next-generation cancer vaccines., The study was mainly funded by the Agencia Española de Investigación (AEI) through the project PID2022-136845OB-10/AEI/10.13039/501100011033 to E.V. and by AGAUR through the project SGR 2021 00092 to A.V. We would like to thank the ISCIII for funding CIBER-BBN (CB06/01/0014 and NANOREMOTE) and the Ministry of Science for funding the ICTS Platform Nanbiosis. The production of the fusion proteins was assisted, in part, by the Protein Production (PPP) Unit of the Platform Nanbiosis of the CIBER-BBN/IBB. Molecular graphics were performed with UCSF Chimera and ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from the National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. ESI-TOF and ICP-MS experiments were performed at Servei d'Anàlisi Química (SAQ) in Universitat Autònoma de Barcelona (UAB). Fluorimetry experiments were performed at Servei de Genòmica i Espectroscòpia de Biomolècules (SGiEB) in UAB. Electron microscopy was performed at the Servei de Microscòpia i Difracció de Raigs X (UAB). MALDI-TOF experiments were performed at Unitat d'Espectrometria de Masses de Caracterització Molecular CCiTUB in Universitat de Barcelona (UB)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A structurally dynamic pathogen-mimicking biomaterial is an efficient activator of dendritic cells

  • Lopez Laguna, Hector
  • Favaro, Marianna TP
  • Chellou Bakkali, Sara
  • Voltà Durán, Eric
  • Parladé Molist, Eloi
  • Márquez Martínez, Mercedes
  • Costa, Manuela
  • Roher Armentia, Nerea
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
Structural dynamism confers intriguing applications to biocompatible materials. Here, we present a protein-based, self-organizing microscale material designed to mimic pathogen-like features. In this formulation, the building block proteins shift their organization through monomeric, microscale, or oligomeric nanoscale states, which is expected to enhance antigen uptake and immune activation. To validate the system, several CT26-derived tumor neoantigens, namely, Ubqln1, AHSL and Phf3, have been assembled as mixed granules, leaking nanoscale protein oligomers. When challenging dendritic cells, this formulation enhanced the expression of the activation markers CD40 and MHC II compared with soluble antigens, underscoring the material’s ability to potentiate antigen-presenting functions. While many antigens are attractive targets due to their unique expression in malignant cells, their poor immunogenicity in soluble versions may render them ineffective. The present approach represents a transversal and feasible tool to enhance the immunogenicity of protein antigens through a dynamic material platform that expands their translational potential., The study was mainly funded by the Agencia Española de Investigación (AEI) through the project PID2022− 136845OB-10/AEI/10.13039/501100011033 to E.V. and by AGAUR through the project SGR 2021 00092 to A.V. H.L.L. was supported by a JDC2023−051795-I. We would like to thank the ISCIII for funding CIBER-BBN (CB06/01/0014 and NANOREMOTE) and the Ministry of Science for funding the ICTS Platform Nanbiosis., Peer Reviewed, 3 - Salut i Benestar, Postprint (published version)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Di Somma, Angela|||0000-0003-4916-7875
  • Livieri, Andrea|||0000-0002-0724-373X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Developing time-sustained drug delivery systems is a main goal in innovative medicines. Inspired by the architecture of secretory granules from the mammalian endocrine system it has generated non-toxic microscale amyloid materials through the coordination between divalent metals and poly-histidine stretches. Like their natural counterparts that keep the functionalities of the assembled protein, those synthetic structures release biologically active proteins during a slow self-disintegration process occurring in vitro and upon in vivo administration. Being these granules formed by a single pure protein species and therefore, chemically homogenous, they act as highly promising time-sustained drug delivery systems. Despite their enormous clinical potential, the nature of the clustering process and the quality of the released protein have been so far neglected issues. By using diverse polypeptide species and their protein-only oligomeric nanoscale versions as convenient models, a conformational rearrangement and a stabilization of the building blocks during their transit through the secretory granules, being the released material structurally distinguishable from the original source is proved here. This fact indicates a dynamic nature of secretory amyloids that act as conformational arrangers rather than as plain, inert protein-recruiting/protein-releasing granular depots.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles

  • Parladé, Eloi|||0000-0001-5750-550X
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Surface-exposed calreticulin (CRT) serves as a crucial cell damage-associated molecular pattern for immunogenic apoptosis, by generating an "eat me" signal to macrophages. Aiming at precision immunotherapies we intended to artificially label tumoral cells in vivo with a recombinant CRT, in a targeted way. For that, we have constructed a CRT fusion protein intended to surface attach CXCR4 cancer cells, to stimulate their immunological destruction. As a targeting ligand of the CRT construct and to drive its specific cell adhesion, we used the peptide V1, a derivative of the vMIP-II cytokine and an antagonist of CXCR4. The modular protein tends to self-assemble as regular 16 nm nanoparticles, assisted by ionic Zn. Through both in vivo and in vitro experiments, we have determined that CRT itself confers cell targeting capabilities to the construct overcoming those of V1, that are only moderate. In particular, CRT binds HeLa cells in absence of further internalization, by a route fully independent of CXCR4. Furthermore, by cytometry in THP-1 cells, we observed that the binding of the protein is preferential for dead cells over live cells, a fact that cannot be associated to a mere artefactual adsorption. These data are discussed in the context of the oligomerizing properties of CRT and the potential clinical applicability of proteins and protein materials functionalized with this novel cell surface ligand.